|

A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy

RECRUITINGSponsored by Boryung Pharmaceutical Co., Ltd
Actively Recruiting
SponsorBoryung Pharmaceutical Co., Ltd
Started2024-09-30
Est. completion2027-03
Eligibility
Age19 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06649162

Summary

The purpose of this study is to identify the risk of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes in clinical practice and to evaluate the clinical usefulness of Dapagliflozin/Pioglitazone combination therapy

Eligibility

Age: 19 Years+Healthy volunteers accepted
Inclusion Criteria:

* Among patients with type 2 diabetes, those who are scheduled to administer a fixed-dose combination of dapagliflozin/pioglitazone at baseline (visit 1)
* Those who voluntarily signed a written personal information collection and usage agreement after listening to an explanation about the objective and method, etc. of this clinical study.

Exclusion Criteria:

* Those who have a history of taking a fixed-dose combination of dapagliflozin/pioglitazone at baseline (visit 1).
* Those who are expected to need insulin prescription during the study period.

Conditions3

DiabetesLiver DiseaseType 2 Diabetes

Browse More Trials

Diabetes trialsLiver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.